Quality of Anticoagulation Control in Atrial Fibrillation
Lancet 376:935-937, Lane,D.A. &Lip,G.Y.H., 2010
Safety and Efficacy of Natalizumab in Children With Multiple Sclerosis
Neurol 75:912-917, Ghezzi,A.,et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Treatment of CNS Sarcoidosis with Infliximab and Mycophenolate Mofetil
Neurol 72:337-340, Morovan,M. &Segal,B.M., 2009
Immunologic, Clinical, and Radiologic Status 14 Months After Cessation of Natalizumab Therapy
Neurol 72:396-401,392, Stuve,O.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinsons Disease
NEJM 361:1268-1278, 1304, Olanow,C.,et al, 2009
Dabigatran Versus Warfarin in Patients with Atrial Fibrillation
NEJM 361:1139-1151, 1200, Connolly,S.,et al, 2009
Progressive Multifocal Leukoencephalopathy After Natalizumab Monotherapy
NEJM 361:1081-1087, Linda,H.,et al, 2009
Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab
NEJM 361:1075-1080, Wenning,W.,et al, 2009
Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009
Multiple Sclerosis Therapeutics: Unexpected Outcomes Clouding Undisputed Successes
Neurol 72:1008-1015, Wiendl,H. &Hohlfeld,R., 2009
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009
Diagnosis and New Treatment in Muscle Channelopathies
JNNP 80:360-365, Meola,G.,et al, 2009
Recurrent Pericarditis Due to Natalizumab Treatment
Neurol 72:1616-1617, Cohen,M.,et al, 2009
Donepezil Treatment of Patients with MCI: A 48-Week Randomized, Placebo-Controlled Trial
Neurol 72:1555-1561, Doody,R.S.,et al, 2009
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
Statin Therapy After First Stroke Reduces 10-Year Stroke Recurrence and Improves Survival
Neurol 72:1816-1822, Milionis,H.J.,et al, 2009
Toxic and Drug-Induced Myopathies
JNNP 80:832-838, Dalakas,M.C., 2009
Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009
Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Stroke 40:3526-3531,3413, Goldstein,L.,et al, 2009
Interventions in the Management of Serum Lipids for Preventing Stroke Recurrence
Stroke 40:e622-e623, Manktelow,B. &Potter,J., 2009
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009
Long-Term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-a-Blocker Therapy
JAMA Neurol 66:490-497, Lozeron, P.,et al, 2009
Herpes Simplex Encephalitis during Treatment with Tumor Necrosis Factor- Inhibitors
CID 49:924-927, Bradford, R.D.,et al, 2009
Safety of Biologic Agents After Rituximab Therapy in Patients With Rheumatoid Arthritis
Rheum Int: December 2009, Mishra, R.,et al, 2009
A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy
Mod Rheumatol 18:399-402, Kameda, T.,et al, 2008
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
NEJM 358:676-688, Hauser,S.L.,et al, 2008
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Postwithdrawal Rebound Increase in T2 Lesional Activity in Natalizumab-Treated MS Patients
Neurol 70:1150-1151,1073, Vellinga,M.M.,et al, 2008
Statin Therapy for Stroke Prevention
Stroke 39:1042-1048, Nassief,A. &Marsh,J.D., 2008
Acute Treatment and Prevention of Menstrually Related Migraine Headache: Evidence-Based Review
Neurol 70:1555-1563, Pringsheim,T.,et al, 2008
Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment
Neurol 70:2024-2035, Winblad,B.,et al, 2008
Lymphomatoid Granulomatosis Involving Central Nervous System Successfully Treated With Rituximab alone
Arch Neurol 65:662-665, Ishiura,H.,et al, 2008
A Randomized Placebo-Controlled Trial of Ginkgo Biloba for the Prevention of Cognitive Decline
Neurol 70:1807-1817,1730, Dodge,H.H.,et al, 2008
Hemorrhagic Stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study
Neurol 70:2364-2370,2355, Goldstein,L.B.,et al, 2008
Anti-Tumor Necrosis Factor Alpha-Associated Multiple Sclerosis
AJNR 26:1548-1550, Titelbaum,D.S.,et al., 2008
Effect of Simvastatin on Cognitive Functioning in Children With Neurofibromatosis Type 1: A Randomized Controlled Trial
JAMA 300:287-294, Krab,L.C.,et al., 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008
Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women: Secondary Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study
Stroke 39:2444-2448, Goldstein,L.B.,et al., 2008
A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008
Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
NEJM 359:1225-1237, Yusuf,S.,et al, 2008
Combining Beta Interferon and Atorvastatin May Increase Disease Activity in Multiple Sclerosis
Neurol 71:1390-1395,1386, Birnbaum,G.,et al, 2008
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Treatment of Ocular Symptoms in Myasthenia Gravis
Neurol 71:1335-1341, Bhanushali,M.J.,et al, 2008
Natalizumab Use in Pediatric Multiple Sclerosis
Arch Neurol 65:1655-1658, Huppke,P.,et al, 2008